The independent source for health policy research, polling, and news.
321-340 of 704 results
California Gov. Gavin Newsom signed off on an array of health care bills that will significantly affect the lives of Californians, including many college students, pregnant women, schoolchildren and dialysis patients.
Pharmaceutical companies raised the wholesale cost of their drugs by a median of nearly 26% from 2017 to early 2019, according to California鈥檚 first-ever report stemming from a new drug price transparency law. Prices for generic drugs rose nearly 38% during that time.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
For more than a decade, customers used the online plan finder to compare dozens of policies. Yet after a redesign of the website, the search results no longer list which plan offers a customer the best value. Federal officials say it will be fixed before enrollment begins next week.
Washington is abuzz with impeachment talk, but what impact would such a move have on congressional action on prescription drug prices and surprise bills? Also, a study out this week shows that health insurance costs for both employers and workers continue to rise. This week, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
The reasons behind one particular shortage of a therapy known as IVIG are complicated, stemming from increased demand and the medication鈥檚 long production window.
The House speaker announced her plan for lowering drug prices, which includes negotiations between drugmakers and federal health officials.
Tennessee wants to convert its Medicaid program to a block grant. But is its plan legal? Meanwhile, Congress continues to struggle with legislation to rein in prescription drug prices and surprise medical bills. This week, Anna Edney of Bloomberg News, Jennifer Haberkorn of the Los Angeles Times and Kimberly Leonard of the Washington Examiner join KHN鈥檚 Julie Rovner to discuss these issues and more. Rovner also interviews Dr. Marty Makary, author of the new book 鈥淭he Price We Pay鈥 about why health care costs so much.
Illegal medications, sold in immigrant communities around the United States, can cause serious harm to consumers, authorities say. Law enforcement officers are cracking down, but some think more must be done.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Nearly 2 million more Americans were uninsured in 2018 than in the previous year, according to the Census Bureau鈥檚 annual report. Plus, the Trump administration announced plans to ban flavored vape liquids, and Congress is back and working to address high prescription drug prices and 鈥渟urprise鈥 medical bills. This week, Joanne Kenen of Politico, Tami Luhby of CNN and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more.
Almost 80% of Americans support efforts in Congress to protect patients from bills that come from doctors or hospitals that were outside their insurance network.
So far this year, 33 states have enacted more than 50 measures to address drug prices, affordability and access. Congress is eyeing the efforts to see what works.
KHN's Sarah Varney discussed opioid painkillers in India with NPR's Rachel Martin on "Morning Edition" Thursday.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
Germany鈥檚 pharmacies provide insights into the country鈥檚 low drug prices and strict regulations. But they鈥檙e still businesses.
As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients鈥 pain, the nation鈥檚 sprawling, cash-fed health care system is ripe for misuse.
What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.
Congress has a variety of reforms in mind that could roil the drugmaking business and potentially slash prices.
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
漏 2026 KFF